What is Tagomics?
Founded in 2020, Tagomics operates at the intersection of genomics and clinical diagnostics. The company specializes in developing a sophisticated platform that integrates multi-omics data to offer a holistic view of disease progression and patient health. By focusing on high-resolution molecular insights, Tagomics aims to redefine how clinicians approach diagnosis and personalized treatment strategies. Headquartered in the United Kingdom, the firm leverages the region's deep-tech ecosystem to advance its research and development efforts, targeting significant improvements in patient care through data-driven innovation.
How much funding has Tagomics raised?
Tagomics has raised a total of $8.5M across 1 funding round:
Other Financing Round
$8.5M
Other Financing Round (2024): $8.5M with participation from Calculus Capital, Illumina Ventures, and IQ Capital
Key Investors in Tagomics
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on high-growth technology and healthcare sectors.
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, dedicated to supporting innovations that enhance human health through life science research and gene editing technologies.
IQ Capital
IQ Capital is a Cambridge and London-based venture firm that invests in deep-tech sectors, including machine learning and disruptive algorithms, with a focus on companies capable of global market dominance.
What's next for Tagomics?
With this major enterprise-level funding, Tagomics is poised to transition into a more aggressive growth phase. The strategic roadmap likely includes expanding its research capabilities, enhancing its diagnostic platform's sensitivity, and pursuing key clinical partnerships to validate its technology in real-world settings. As the company scales, it will focus on solidifying its market position within the competitive genomics sector, ensuring that its diagnostic solutions are integrated into standard clinical workflows. The support from specialized investors provides not only the necessary liquidity but also the industry expertise required to navigate the complex regulatory and commercial pathways inherent in the life sciences industry.
See full Tagomics company page
